Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly Gundacker

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Blood|June 19, 2002
Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group studySandra R Wolman, Holly Gundacker, Frederick R Appelbaum, et al.
Blood|February 4, 2006
Age and acute myeloid leukemiaFrederick R Appelbaum, Holly Gundacker, David R Head, et al.
Blood|May 10, 2011
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605Mikkael A Sekeres, Holly Gundacker, Jeffrey Lancet, et al.
Medical Oncology (Northwood, London, England)|June 26, 2012
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)Peter H Wiernik, Zhuoxin Sun, Holly Gundacker, et al.
International Journal of STD & AIDS|October 20, 2018
Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender womenRoss D Cranston, Alex Carballo-Diéguez, Holly Gundacker, et al.
British Journal of Haematology|October 14, 2009
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaThomas R Chauncey, Holly Gundacker, Mazyar Shadman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2018
Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal RingsCraig J Hoesley, Beatrice A Chen, Peter L Anderson, et al.
Journal of the International AIDS Society|March 6, 2024
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United StatesAlbert Y Liu, Holly Gundacker, Barbra Richardson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2019
Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017)Albert Y Liu, Aliza Norwood, Holly Gundacker, et al.
Plos One|June 5, 2024
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal ringsSharon L Achilles, Clifton W Kelly, Craig J Hoesley, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Blood|June 19, 2002
Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group studySandra R Wolman, Holly Gundacker, Frederick R Appelbaum, et al.
Blood|February 4, 2006
Age and acute myeloid leukemiaFrederick R Appelbaum, Holly Gundacker, David R Head, et al.
Blood|May 10, 2011
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605Mikkael A Sekeres, Holly Gundacker, Jeffrey Lancet, et al.
Medical Oncology (Northwood, London, England)|June 26, 2012
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)Peter H Wiernik, Zhuoxin Sun, Holly Gundacker, et al.
International Journal of STD & AIDS|October 20, 2018
Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender womenRoss D Cranston, Alex Carballo-Diéguez, Holly Gundacker, et al.
British Journal of Haematology|October 14, 2009
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaThomas R Chauncey, Holly Gundacker, Mazyar Shadman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2018
Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal RingsCraig J Hoesley, Beatrice A Chen, Peter L Anderson, et al.
Journal of the International AIDS Society|March 6, 2024
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United StatesAlbert Y Liu, Holly Gundacker, Barbra Richardson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2019
Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017)Albert Y Liu, Aliza Norwood, Holly Gundacker, et al.
Plos One|June 5, 2024
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal ringsSharon L Achilles, Clifton W Kelly, Craig J Hoesley, et al.
Pageof 2